SLC17A2 Antibody

What is SLC17A2 and why is it an important research target?

SLC17A2 (Solute Carrier Family 17 Member 2) is a membrane protein involved in ion transport, particularly as a sodium/phosphate cotransporter (also known as NPT3). In humans, the canonical protein consists of 439 amino acid residues with a molecular mass of approximately 47.3 kDa. It is an important research target because it plays critical roles in phosphate homeostasis and organic anion transport across various tissues. Recent research has shown that SLC17A2 functions as a polyspecific organic anion transporter involved in the circulation of compounds such as urate throughout the body, making it relevant for studies in renal physiology, drug excretion, and metabolic disorders .

What tissues express SLC17A2 protein, and how should I design my experiments accordingly?

SLC17A2 demonstrates a relatively wide tissue distribution pattern, with significant expression in:

When designing experiments, consider using appropriate positive control tissues based on this expression pattern. For instance, kidney or small intestine tissue would be optimal positive controls for western blotting or immunohistochemistry experiments .

How do I select the most appropriate SLC17A2 antibody for my experiments?

Selection of an appropriate SLC17A2 antibody depends on several factors:

• Target species: Ensure the antibody has confirmed reactivity against your species of interest (human, mouse, rat, etc.)

• Target region: Different antibodies target different regions of SLC17A2:

  • N-terminal region antibodies

  • Middle region antibodies (residues around positions 230-330)

  • Internal region antibodies

• Application compatibility: Verify that the antibody has been validated for your specific application:

  • Western blotting (most widely validated)

  • ELISA

  • Immunohistochemistry

  • Immunofluorescence

• Clonality: Most available SLC17A2 antibodies are rabbit polyclonal, which offers good sensitivity but may have batch-to-batch variation .

What are the optimal experimental conditions for detecting SLC17A2 by Western blotting?

For optimal detection of SLC17A2 by Western blotting:

• Sample preparation:

  • Use membrane-enriched fractions as SLC17A2 is a membrane protein

  • Include protease inhibitors to prevent degradation

  • Consider detergent solubilization (e.g., 1% NP-40) to extract membrane proteins

• Electrophoresis conditions:

  • Expected molecular weight: ~47-50 kDa for monomeric form

  • Higher molecular weight bands (~68 kDa, ~130 kDa) may represent glycosylated forms or protein complexes

  • Use 8-10% SDS-PAGE gels for optimal resolution

• Transfer and detection:

  • Wet transfer is recommended for membrane proteins

  • Blocking: 5% non-fat dry milk or BSA in TBST

  • Primary antibody dilution: Typically 1:200-1:1000 (optimize for specific antibody)

  • Secondary antibody: Anti-rabbit HRP-conjugated (typically 1:5000)

• Controls:

  • Positive control: Kidney or small intestine tissue lysate

  • Negative control: Tissues with minimal expression or antibody pre-absorption with immunogenic peptide .

How can I validate the specificity of my SLC17A2 antibody?

To validate SLC17A2 antibody specificity, employ multiple complementary approaches:

• Immunoblotting with recombinant proteins:

  • Test against purified SLC17A2 protein

  • Test against other SLC17 family members to confirm no cross-reactivity

• Peptide competition assay:

  • Pre-incubate antibody with excess immunizing peptide

  • Observe elimination of specific signal in positive tissues

• Knockout/knockdown validation:

  • Compare signal in wild-type vs. SLC17A2 knockout tissues

  • Or use siRNA-mediated knockdown in cell lines

• Multiple antibody approach:

  • Use antibodies targeting different epitopes of SLC17A2

  • Compare signal patterns across different tissues .

What are the common pitfalls when performing immunohistochemistry with SLC17A2 antibodies?

When performing immunohistochemistry with SLC17A2 antibodies, be aware of these common pitfalls:

• Membrane protein localization challenges:

  • Inadequate fixation may cause antigen masking

  • Overfixation may destroy epitopes

  • Use antigen retrieval methods optimized for membrane proteins

• Background and non-specific staining:

  • Cross-reactivity with other SLC family members

  • Non-specific binding to highly vascular tissues

  • Use appropriate blocking (serum from secondary antibody species)

• False negatives:

  • Glycosylation may mask epitopes in certain tissues

  • Consider multiple antibodies targeting different regions

  • Optimize antibody concentration (typical range: 1:50-1:200)

• Interpretation errors:

  • Subcellular localization varies by tissue (apical membrane in kidney, cytoplasmic in others)

  • Co-staining with membrane markers helps confirm localization .

How do glycosylation states affect SLC17A2 detection, and how can I address this in my research?

SLC17A2 undergoes significant post-translational modifications, particularly glycosylation, which impacts antibody detection:

• Impact on apparent molecular weight:

  • Native SLC17A2: ~47-50 kDa

  • Glycosylated forms: ~65-70 kDa

  • Protein complexes: ~130 kDa

• Tissue-specific glycosylation patterns:

  • Kidney exhibits different glycosylation patterns than intestinal SLC17A2

  • This may affect antibody binding efficiency

• Methodological approaches:

  • Deglycosylation treatment: Use N-glycosidase F (PNGase F) or O-glycosidase with neuraminidase

  • Heat treatment (75°C for 15 min in 0.5% SDS and 40 mM DTT) prior to glycosidase treatment

  • Compare molecular weight shifts before and after enzyme treatment

• Antibody selection considerations:

  • Choose antibodies targeting protein regions less affected by glycosylation

  • For heavily glycosylated tissues, antibodies against the middle region may provide more consistent results .

How can I design experiments to distinguish between SLC17A2 and other SLC17 family members?

Distinguishing SLC17A2 from other SLC17 family members requires careful experimental design:

• Antibody specificity verification:

  • Test antibodies against recombinant proteins of multiple SLC17 family members

  • Use tissues from knockout models as negative controls

• Functional characterization approaches:

  • SLC17A2 transports phosphate via Na+ cotransport and various organic anions

  • Design transport assays with specific substrates (PAH, urate)

  • Use inhibitors with differential effects: DIDS and Evans blue inhibit most SLC17 transporters, but with different potencies

• Expression pattern analysis:

  • Use RT-PCR with highly specific primers targeting unique regions

  • Compare expression patterns across tissues (SLC17A2 has distinct expression in kidney, intestine, and liver)

• Subcellular localization studies:

  • Co-localization with organelle markers

  • SLC17A2 is primarily found in plasma membranes, unlike some other family members that localize to vesicular membranes .

What techniques can I use to study SLC17A2 transport function in conjunction with antibody-based detection methods?

To comprehensively characterize SLC17A2 transport function alongside antibody detection:

• Proteoliposome reconstitution assays:

  • Purify SLC17A2 protein (using antibody-based methods if needed)

  • Reconstitute into proteoliposomes

  • Measure transport of radiolabeled substrates (PAH, urate, phosphate)

  • Create artificial membrane potential using ionophores (e.g., valinomycin)

• Cell-based transport assays:

  • Express SLC17A2 in heterologous systems (Xenopus oocytes, HEK293 cells)

  • Confirm expression by immunoblotting or immunofluorescence

  • Measure uptake of radiolabeled substrates

  • Use inhibitors to confirm specificity

• Ex vivo tissue studies:

  • Prepare brush-border membrane vesicles from kidney or intestine

  • Verify SLC17A2 presence by immunoblotting

  • Perform transport assays with radiolabeled substrates

  • Correlate transport activity with protein expression levels

• In vivo functional studies:

  • Use antibodies to quantify SLC17A2 expression in different physiological states

  • Correlate with measurements of phosphate or organic anion transport in appropriate tissues .

How do I interpret multiple bands in Western blots when using SLC17A2 antibodies?

Multiple bands in SLC17A2 Western blots are common and can be interpreted as follows:

• Expected band patterns:

  • ~47-50 kDa: Monomeric, unmodified SLC17A2

  • ~65-70 kDa: Glycosylated forms

  • ~130 kDa: Potential dimers or protein complexes

• Verification approaches:

  • Deglycosylation treatment: If bands shift to lower molecular weight after PNGase F treatment, they represent glycosylated forms

  • Reducing vs. non-reducing conditions: Persistence of high molecular weight bands under reducing conditions suggests stable complexes rather than disulfide-linked dimers

  • Cross-linking experiments: Chemical cross-linkers can stabilize transient protein-protein interactions

• Tissue-specific considerations:

  • Kidney samples typically show higher molecular weight forms due to extensive glycosylation

  • Liver and intestine may show different patterns

• Antibody-specific patterns:

  • Antibodies targeting different regions may recognize different glycoforms or cleaved products .

What are the best approaches to quantify SLC17A2 protein expression levels across different tissues?

For accurate quantification of SLC17A2 expression across tissues:

• Sample preparation standardization:

  • Use consistent membrane enrichment protocols

  • Normalize to total membrane protein rather than total protein

  • Consider detergent solubilization optimization for each tissue type

• Quantitative Western blotting:

  • Include recombinant SLC17A2 standards of known concentration

  • Use fluorescent secondary antibodies for wider linear range

  • Account for all immunoreactive bands (glycosylated forms, complexes)

  • Use tissue-specific loading controls (Na+/K+-ATPase for membrane fractions)

• Quantitative immunohistochemistry:

  • Use automated image analysis software

  • Include standardized positive controls in each batch

  • Consider tissue microarrays for multi-tissue comparison

  • Use multiplexed staining to normalize to cell-type specific markers

• Complementary approaches:

  • Correlate protein data with mRNA quantification (RT-qPCR)

  • Use mass spectrometry-based proteomics for absolute quantification .

How can I resolve discrepancies between mRNA expression data and antibody-based protein detection for SLC17A2?

Discrepancies between mRNA and protein detection for SLC17A2 are common and can be addressed by:

• Technical verification:

  • Confirm antibody specificity using knockout controls or peptide competition

  • Verify primer specificity for RT-PCR using sequencing of amplicons

  • Test multiple antibodies targeting different epitopes

  • Use multiple reference genes for RT-qPCR normalization

• Biological considerations:

  • Post-transcriptional regulation: miRNAs may suppress translation without affecting mRNA levels

  • Protein stability: SLC17A2 may have tissue-specific degradation rates

  • Post-translational modifications: Extensive glycosylation may mask epitopes in protein-rich areas

  • Subcellular trafficking: Protein may be retained intracellularly in some tissues

• Methodological approach:

  • Perform time-course studies to detect temporal disconnects between mRNA and protein

  • Use cell fractionation to detect intracellular protein pools

  • Consider pulse-chase experiments to determine protein half-life in different tissues

• Integrated analysis:

  • Correlate functional transport assays with both mRNA and protein data

  • Consider proteogenomic approaches combining RNA-seq with mass spectrometry .

How can I use SLC17A2 antibodies in studies of drug transport and pharmacokinetics?

SLC17A2 antibodies can be valuable tools in drug transport studies:

• Expression correlation with drug disposition:

  • Quantify SLC17A2 expression in drug elimination organs (kidney, liver)

  • Correlate expression levels with drug clearance parameters

  • Compare expression across species for translational research

• Drug-transporter interaction studies:

  • Use immunoprecipitation with SLC17A2 antibodies followed by mass spectrometry

  • Identify drug compounds that physically interact with the transporter

  • Confirm functional relevance with transport assays

• Pharmacological modulation:

  • Monitor SLC17A2 expression changes in response to drug treatments

  • Use antibodies to track subcellular localization changes during drug exposure

  • Develop cell-based high-throughput screening assays using antibody-based detection

• In vivo applications:

  • Use immunohistochemistry to examine expression changes in disease models

  • Correlate with altered drug disposition profiles

  • Consider therapeutic targeting of SLC17A2 for drug delivery .

What are the best practices for using SLC17A2 antibodies in multiplex immunofluorescence studies?

For successful multiplex immunofluorescence with SLC17A2 antibodies:

• Panel design considerations:

  • Combine with markers for:

    • Cell type identification (e.g., CD31 for endothelial cells, GFAP for astrocytes)

    • Subcellular compartment markers (Na+/K+-ATPase for basolateral membrane)

    • Other transporters for co-localization studies

• Technical optimization:

  • Sequential staining approach: Perform complete antibody incubation and detection for one marker before starting the next

  • Antibody stripping between rounds: Use gentle elution buffers to remove previous antibodies

  • Direct conjugation: Consider directly labeled primary antibodies to avoid species cross-reactivity

• Validation approaches:

  • Single staining controls to confirm specificity

  • Fluorescence minus one (FMO) controls to set thresholds

  • Spectral unmixing to address autofluorescence

• Analysis strategies:

  • Quantify co-localization using Pearson or Manders coefficients

  • Perform cell-by-cell quantification of multiple markers

  • Consider 3D reconstruction for membrane protein visualization .

How can I use SLC17A2 antibodies to investigate the role of this transporter in disease models?

To investigate SLC17A2 in disease models using antibodies:

• Expression analysis in disease states:

  • Compare SLC17A2 expression in normal vs. pathological tissues

  • Quantify expression changes during disease progression

  • Correlate with clinical parameters or biomarkers

• Mechanistic studies:

  • Use antibodies to track subcellular redistribution in disease states

  • Examine post-translational modifications specific to disease conditions

  • Investigate protein-protein interactions that may be altered in disease

• Therapeutic intervention monitoring:

  • Track SLC17A2 expression changes in response to treatments

  • Use as a biomarker for treatment efficacy

  • Develop companion diagnostics for therapies targeting related pathways

• Disease-relevant experimental models:

  • For hyperuricemia/gout: Examine SLC17A2 expression in kidney and intestine

  • For renal disorders: Investigate expression changes in different nephron segments

  • For metabolic diseases: Study expression in liver and relationship to metabolite transport

Research has shown that SLC17A2 functions as a polyspecific organic anion transporter that may play roles in urate homeostasis and drug disposition, making it potentially relevant for diseases involving these pathways .